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Abstract
2q  .Spontaneous Ni entry leak , measured as fluorescence quench in fura-2-loaded HL-60 cells at the excitation
 . 2qwavelength of 360 nm, was strongly inhibited by tetrandrine TET, 100 mM , a Ca antagonist of Chinese herbal origin.
 .Exposure of the cells for 5 min to saponins from Quillaja saponaria QS, 30 mgrml , surfactants well known to
permeabilize the plasma membrane by complexing with cholesterol, promoted Ni2q entry without causing fura-2 leak-out.
 . 2qUnexpectedly, TET caused an immediate within 2.5 min augmentation of QS-promoted Ni entry; and a 5-min treatment
2q with both TET and QS resulted not only in an enhanced Ni entry, but also a fura-2 leak-out. Ginseng saponins 100
.mgrml alone or together with TET did not cause such a permeabilization. Permeabilization induced by 1–3 mM digitonin,
another cholesterol-complexing glycoside, could not be enhanced by TET. TET did not affect permeabilization induced by
 .Triton X-100 0.01% , a detergent which non-specifically disrupts the hydrophobic interaction at the plasma membrane.
2q  .  .TET also did not enhance Ni entry triggered by ionomycin 0.35 mM or SK&F 96365 20 mM . Further, it did not
2q  .augment Ni entry when the plasma membrane fluidity was modulated by changes of temperature 27–478C or treatment
with 5% ethanol. This QS-promoted Ni2q entry could not be amplified by other lipophilic Ca2q antagonists, such as
 .  . 2q diltiazem 100 mM and verapamil 100 mM . The results hence indicate that TET enhanced Ni entry or permeabiliza-
.tion elicited by QS treatment, but not other perturbations of the plasma membrane. We suggest that pore formation at the
plasma membrane, a consequence of QS-cholesterol interaction, can be specifically enhanced by TET. Also, a comparative
study of the effects of TET and its very close analogues, hernandezine and berbamine, reveals that the methoxyl group at
the R position of TET appears to be crucial in enhancing QS-promoted Ni2q entry.2
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1. Introduction
 .Tetrandrine TET , a bis-benzylisoquinoline alka-
loid isolated from the Chinese medicinal herb
 .Stephania tetrandra Fig. 1 , has been demonstrated
to be an effective hypotensive and antisilicotic drug
w xin animal experiments and clinical studies 1–4 . The
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Fig. 1. Chemical structures of tetrandrine, hernandezine and
berbamine.
hypotensive effect of TET is believed to be due to its
blockade of L-type voltage-operated Ca2q channels
 . w xVOCC 5,6 . TET also inhibits T- and N-type VOCC
w xin a number of excitable tissues 5,7–9 . More re-
cently, TET was shown to act on Ca2q channels not
opened by depolarization. For instance, TET inhibits
the agonist-activated Ca2q entry in vascular smooth
w x 2qmuscles 10,11 and blocks Ca entry activated by
 2qthapsigargin an endoplasmic reticulum Ca pump
. 2qinhibitor as a result of intracellular Ca store deple-
tion in HL-60 cells, 3T3 fibroblasts, rat glioma C6
w xcells and parotid acinar cells 12,13 . TET also affects
targets other than Ca2q channels, such as Ca2q-
activated Kq channels, Naq,Kq-ATPases and protein
w xkinase C 5,14,15 . These observations may explain
the modulatory effects of TET on many biological
w xresponses in vitro and in vivo 5 , but on the other
hand, they cast doubt on the specificity of TET as a
Ca2q antagonist.
Emptying of the intracellular Ca2q store following
agonist stimulation or thapsigargin treatment acti-
2q 2q vates the entry of Ca and Mn a surrogate ion
2q.for Ca through plasmalemmal channels in many
w xcell types including HL-60 cells 12,13,16,17 . It was
previously shown in our laboratory that such store-
operated divalent cation entry in HL-60 cells could
w xbe strongly inhibited by TET 12 . More recently, we
also identified the chemical moiety of TET which
was crucial for the above-mentioned inhibitory action
w x  .18 . In this work, using the same cell system HL-60 ,
we tested the specificity of TET as a Ca2q antago-
nist: if TET blocks the divalent cation entry by acting
specifically on Ca2q channels, then it presumably
would not affect cation influx that is promoted by
 .Quillaja saponins QS . The latter are plant glyco-
sidic compounds which form pores at the plasma
membrane by causing aggregation of cholesterol
w x19,20 . Unexpectedly we observed that TET acceler-
ated the entry of Ni2q which was promoted by QS.
However, TET did not accelerate the influx of Ni2q
when the fluidity of the plasma membrane was modu-
lated or when the hydrophobic association in the
plasma membrane was non-specifically disrupted. We
here show evidence that TET-QS interaction bears a
stringency in structural requirements. The TET-QS
interaction will also be discussed in the context of
their frequent uses in basic research and their poten-
tial therapeutic values.
2. Materials and methods
2.1. Cell culture
HL-60 cells obtained from American Type Culture
Collection, Maryland, were maintained in RPMI 1640
 .medium Sigma Chem. Co. supplemented with 10%
fetal calf serum, 5 mg gentamycinrml and peni-
 .cillinrstreptomycin 100 Urml, 100 mgrml in a
humidified atmosphere with 5% CO at 378C. The2
cells were split in a 1:5 ratio every two or three days.
2.2. Materials
 .QS product number S2149 and S7900 , iono-
mycin, Triton X-100, verapamil, thapsigargin, digi-
tonin, filipin and fura 2-AM were obtained from
Sigma Chemical Co., St. Louis, USA. S2149 and
S7900 QS are both from Quillaja bark but are from
different primary sources. Unless otherwise stated,
S2149 QS was used in all the experiments. Saponins
 .number 7695, plant source unknown were also pur-
 .chased from E. Merck Darmstadt, Germany . Gin-
seng saponins were from Sanchakou Ginsenoside
 .Company Heilongjiang, China . Diltiazem was from
 .Calbiochem La Jolla, CA . Fetal calf serum was
purchased from Gibco BRL Gaithersburg, MD,
.USA . SK&F 96365 was from BIOMOL Research
Lab., Plymouth Meeting, PA, USA. Tetrandrine
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 .  .TET purity)98% was purchased from Aldrich
 .  .Milwaukee, WI, USA . Hernandezine HER was a
generous gift from Professor G.Z. Liu of the China-
 .Japan Friendship Hospital Beijing, China . Both TET
and HER were dissolved in 0.1 N HCl to yield a
stock solution of 30 mM. The amount of vehicle
added to the reaction medium did not affect the
medium pH or the fluorescence reading. Berbamine
 . BER , kindly provided by Professor M.R. Rao De-
partment of Cardiovascular Pharmacology, Nanjing
.Medical College , was dissolved in distilled water to
yield a stock solution of 30 mM.
[ 2q]2.3. Measurement of Ca and di˝alent cationi
influx
w 2qxThe methods used to measure Ca and thei
influx of divalent cations were as described previ-
w xously 12,21 . Hank’s buffered saline solution
 .  .HBSS , composed of mM NaCl 138, KCl 5.3,
MgSO 0.8, CaCl 1.2, KH PO 0.44, Na HPO4 2 2 4 2 4
 w x0.34, glucose 5, and Hepes N- 2-hydroxyethyl -
X .piperazine-N -2-ethane sulfonic acid 25, buffered at
pH 7.4, was used for washing the cells. HL-60 cells
grown to a density of around 1.5=106rml were
 . 2qharvested, washed once 200=g, 5 min in Ca -
containing HBSS and resuspended in RPMI 1640
medium at a cell density of about 2=107rml. Fura
 .2-acetoxymethyl AM ester was added to this cell
suspension at a final concentration of 5 mM. The cell
suspension was then incubated at 378C for 45 min.
Thereafter, the fura 2-loaded cells were washed twice
 . 2q200=g, 5 min in Ca -containing HBSS and re-
suspended in the same buffer solution at a cell den-
sity of 2.8=106rml. Before experimentation of each
sample, 1 ml of this cell suspension was centrifuged
 .200=g, 5 min and the cell pellet was resuspended
2q  w 2qx .in 2 ml Ca -containing for Ca measurementi
2q or Ca -free HBSS for measurement of divalent
.cation influx . This 2-ml cell suspension was trans-
ferred to a quartz cuvette which contained a mini-
stirrer, and warmed at 378C except in experiments
.shown in Fig. 9 for about 3 min before addition of
drugs or divalent cations. Fura-2 fluorescence was
measured by a Hitachi F-4000 fluorescence spectro-
w 2qxphotometer. For Ca measurement, the excitationi
and emission wavelengths were set at 340 nm and
500 nm respectively. Fluorescence was not calibrated
w 2qxinto Ca but instead expressed in arbitrary unitsi
because of the possible fura-2 leak-out of the cells
 .after prolonged QS treatment see Fig. 3 . For the
measurement of Mn2q and Ni2q influx, the excita-
tion and emission wavelengths were set at 360 nm
and 500 nm respectively. At 360 nm excitation wave-
length, the fura-2 fluorescence is insensitive to Ca2q
but quenchable by heavy metals such as Mn2q and
2q w xNi 22 .
2.4. Measurement of fura-2 leak-out
Fura 2-loaded HL-60 cells were washed and pre-
pared as described above. Before experimentation of
each sample, 1 ml of cell suspension was centrifuged
 .200=g, 5 min and the cell pellet was resuspended
in 2 ml Ca2q-free HBSS. This 2-ml cell suspension
was transferred to a quartz cuvette which contained a
mini-stirrer, and warmed at 378C for about 3 min.
Fluorescence was measured as described above exci-
tation and emission wavelengths at 360 nm and 500
.nm respectively . Cells were treated with QS for
around 1 min and then TET various combinations of
.  .concentrations for 2.5 or 5 min Fig. 3 . Subse-
quently the cells were retrieved from the reaction
 .cuvette and rapidly centrifuged 500=g, 50 s . After
that, the supernatant was discarded and the cell pellet
was resuspended again in 2 ml Ca2q-free HBSS.
Fluorescence was measured again and expressed as a
percentage of that before treatments with QS and
 .TET Fig. 3, y-axis . These values indicate the
amount of fura-2 remaining in the cytosol. Control
 .samples i.e., without drug treatment were processed
in the same manner, and the fluorescence in the
control samples dropped by some 15%, which was
most likely due to spontaneous fura-2 leak-out and
also cell loss during the cell retrieval and centrifuga-
tion processes. The differences between the controls
and the drug-treated groups therefore represent the
proportions of fura-2 leak-out caused by drug treat-
ment.
2.5. Statistical analysis
Results are expressed as mean"S.E.M. The Stu-
dent’s paired t-test was employed and differences
were considered significant when P-0.05.
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3. Results
3.1. Effects of TET on QS-induced permeabilization
to Ca2q and fura-2
The plateau phase of the thapsigargin-induced
Ca2q response in Ca2q-containing medium, which
was due to sustained Ca2q entry activated by Ca2q
 2q .store depletion capacitative Ca entry , was sub-
 . w xstantially inhibited by 100 mM TET Fig. 2a 12,18 .
If TET blocks Ca2q entry by specifically interacting
with Ca2q channels, it presumably would not affect
Ca2q entry promoted by QS. The latter acts by
permeabilizing the plasma membrane via complexing
w xwith cholesterol 19,20 . QS at 30 mgrml, a concen-
tration known to permeabilize selectively the plasma
w xmembrane 23–25 , induced a sustained elevation in
 .fluorescence Fig. 2b . As fura-2 would possibly leak
out of the cells after QS-induced permeabilization
 .see below , such elevation in fluorescence could be
w 2qxdue to both an elevation in Ca and saturation ofi
leaked fura-2 with extracellular Ca2q. Therefore, flu-
Fig. 2. Effects of TET on TSG-activated Ca2q entry and QS-in-
duced permeabilization. HL-60 cells in Ca2q-containing HBSS
 .  .were stimulated with a 30 nM TSG and b 30 mgrml QS and
at the sustained phase of fluorescence elevation, 100 mM TET
 .  .was added. c Same conditions as in b , and QS was added after
TET. The y-axis represents fura-2 fluorescence at 340 nm excita-
tion wavelength. Similar traces were obtained in 3 other separate
experiments.
Fig. 3. Effects of QS and TET on fura-2 leak-out. Experimental
details are described in Section 2. Pretreatment fluorescence
 . Xvalues arbitrary units from A to F are, respectively, 46.7"6.1,
47.8"6.4, 48.9"5.9, 49.8"4.8, 53.2"2.2, 50.6"4, 51.8"0.5,
52.5"1.4, 53.1"0.5, 52.3"0.2, 52.9"1.4 and 50.8"2.5. Re-
sults are the mean"S.E.M. of 3–4 separate experiments. ) E and
X  . XE are significantly P -0.05 different from A and A respec-
)) X  .tively. F and F are significantly P -0.05 different from E
X ) ) ) X  .and E respectively. D is significantly P -0.05 different
from CX.
w 2qxorescence was not calibrated into Ca . Additioni
of TET did not suppress such QS-induced fluores-
cence elevation, but instead caused a further rise in
fluorescence. The latter could be explained by the
fact that TET alone induced a rise in fluorescence
 .Fig. 2c , which we have already shown in HL-60
cells to be due to Ca2q release from the intracellular
w xstores 12 . This further suggests that QS at 30 mgrml
did not permeabilize the intracellular Ca2q store
which could be depleted by subsequent addition of
TET. Surprisingly, QS induced a larger elevation in
fluorescence in the presence than in the absence of
TET pretreatment compare Fig. 2c and Fig. 2b; at 12
min after QS exposure, 51.3"5.6% versus 39.8"
.4.9% above pre-treatment level; ns4; P-0.05 ,
suggesting that TET could enhance QS-induced per-
meabilization to Ca2q or leak of fura-2 or both.
We investigated the enhancement by TET of QS-
induced permeabilization by checking the fura-2
leakage. Neither 100 mM TET nor 30 mgrml QS on
its own stimulated fura-2 leakage throughout the
 X X X.5-min time course Fig. 3A,B,C,A ,B ,C . Exposure
to both 100 mM TET and 30 mgrml QS did not
affect the fura-2 leakage during the first 2.5 min but
 .induced a significant P-0.05 leakage after 5 min.
 X.Fig. 3D,D . A 2.5-min treatment was sufficient
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 .P-0.05 for 100 mgrml QS alone to cause a
substantial fura-2 leak-out, which was significantly
 .  .P-0.05 augmented by TET Fig. 3E,F . Further
incubation only marginally increased the leak-out of
 X X.fura-2 Fig. 3E ,F .
3.2. Effects of TET on QS-induced permeabilization
to Ni2q and Mn2q
Another approach to study the effect of TET on
QS-induced permeabilization was to examine the en-
try of divalent cations, such as Ni2q and Mn2q,
w xwhich quench the fura-2 fluorescence 12,21,22 . Ad-
dition of Ni2q caused a gradual quenching, indicating
2q  .that there was a small spontaneous Ni entry leak
into the cytosol Fig. 4a; quenching rate after HCl
treatment was 4.4"1 arbitrary fluorescent unitsr4
. 2qmin; ns4 . The basal Ni entry was blocked by
TET Fig. 4b; quenching rate after TET treatment
was 0.3"0.3 arbitrary fluorescent unitsr4 min; ns
. 4 . Such blockade was statistically significant P-
.  .0.05 . QS 30 mgrml markedly accelerated the
 .quenching Fig. 4c . On the basis of the following
observations, such acceleration of quenching indi-
2q  .cated that QS increased the rate of Ni entry: a QS
 .or TET alone or in combination did not affect the
 . fluorescence 360 nm excitation of fura-2 acid not
.  .  .shown b QS or TET alone or in combination did
not affect the fluorescence of fura-2-loaded cells see
.  .  .Fig. 6 c QS 30 mgrml did not cause fura-2
 X.leak-out even after 5 min see Fig. 3C,C . Addition
Fig. 4. Effects of QS and TET on Ni2q entry. After exposure of
2q 2q HL-60 cells in Ca -free HBSS to 1.2 mM Ni , QS 30
.  .mgrml or water sham treatment was added for around 1 min
 . before further treatment with TET 100 mM or HCl solvent
.control . The y-axis represents fura-2 fluorescence at 360 nm
excitation wavelength. Similar traces were obtained in at least 3
other separate experiments.
2q Fig. 5. Effects of QS and TET on Ni entry quantitative results
.  .of Fig. 4c,d . a The fluorescence changes after HClrTET
 .treatment Fig. 4c,d was quantified at several time points. The
values at the zero time point represent the fluorescence just
before HClrTET treatment. Results are the mean"S.E.M. of 7
) separate experiments. indicates statistical significance P -
.  .0.01 . b Concentration-dependent effects of TET on QS-in-
2q  .duced Ni entry using the protocol shown in Fig. 4d . Symbols
 .used: square, solvent HCl ; diamond, circle, triangle represent
30, 60 and 100 mM TET, respectively. Results are the mean of 4
separate experiments; for clarity, S.E.M. are not shown.
 .of TET accelerated QS-induced quenching Fig. 4d .
The acceleration was immediate and at 1 min the
QS-induced quenching was enhanced by 65% in the
 .presence of TET Fig. 5a . Enhancement by TET of
the QS-induced quenching at earlier time points 1
.  .and 2.25 min Fig. 5a was most likely due to an
enhanced Ni2q entry but not to an increased fura-2
leak-out since there was no fura-2 loss when cells
 .were treated with QS 30 mgrml and TET for 2.5
 ..min Fig. 3D . However, such treatment for 5 min
 X.resulted in a significant fura-2 loss Fig. 3D , which
would in part contribute to the enhancement by TET
of QS-induced quenching at later time points e.g.,
.  . 5.5 min Fig. 5a . Fig. 5b shows that TET 30–100
.mM concentration-dependently enhanced the QS-in-
duced quenching.
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 .QS of another product number S7900 from
Sigma, and hemolytic saponins of unknown plant
.source from E. Merck, were also tested. At 30
mgrml, they both promoted Ni2q entry, which was
further accelerated by TET results not shown but
.were similar to those shown in Fig. 4c,d . Saponins
 .from ginseng i.e., ginsenosides have been shown to
w xbe non-hemolytic even at 200 mgrml 25 . We ob-
served that ginseng saponins, even at 100 mgrml,
did not promote Ni2q entry; and subsequent addition
2q of TET actually retarded the Ni leak not shown
.but similar to that shown in Fig. 4b .
Results consistent with those in Fig. 4 were ob-
served if Ni2q was added after treatment with QS
 .orrand TET Fig. 6 . TET pretreatment inhibited
Ni2q entry, while QS accelerated it. With QS and
TET pretreatment, Ni2q addition resulted in a sudden
and huge drop in fluorescence followed by a gradual
quench. As treatment with both QS and TET for 5
 .min resulted in fura-2 leakage Fig. 3 , the quenching
by Ni2q of extracellular leaked fura-2, together with
the influx of Ni2q into the cytosol, could account for
the initial rapid quench of fluorescence.
To test the ion specificity of the effect of QS and
TET, the entry of Mn2q, which also quenches the
fura-2 fluorescence, was also studied under similar
experimental conditions. Addition of Mn2q, like Ni2q,
also caused a gradual fall in fluorescence, suggesting
2q  .Mn entered the cytosol spontaneously Fig. 7a .
The cells appeared to be much more permeable to
Mn2q than to Ni2q, therefore a lower concentration
2q  .of Mn 0.2 mM was used in order to have a
quenching rate comparable to that of Ni2q. TET
Fig. 6. Effects of QS and TET on Ni2q entry. HL-60 cells in
2q  .Ca -free HBSS were treated with HCl solvent control, ctl , 100
mM TET, 30 mgrml QS or 100 mM TET plus 30 mgrml QS
before 1.2 mM Ni2q addition. The y-axis represents fura-2
fluorescence at 360 nm excitation wavelength. Similar traces
were obtained in 2 other separate experiments.
Fig. 7. Effects of QS and TET on Mn2q entry. After exposure of
2q 2q HL-60 cells in Ca -free HBSS to 0.2 mM Mn , water sham
.  .  .  .treatment a or QS 30 mgrml b was added for around 0.5
 . min before further treatment with TET 100 mM or HCl solvent
.control . The vertical bar represents 4 fura-2 fluorescence units at
360 nm excitation wavelength. Similar traces were obtained in 2
other separate experiments.
2q  .strongly retarded the basal Mn entry Fig. 7a , as
w x 2qwas observed previously 12 . Mn entry was not
accelerated upon the addition of QS compare lower
.trace of Fig. 7a and upper trace of Fig. 7b . The
Mn2q-induced quenching rate in the presence of QS
was not much affected by the addition of TET for 2
min, yet the difference appeared to become more
 .conspicuous after 2.5 min Fig. 7b . This is consistent
with the observation that after 2.5 min, fura-2 leaked
 X.out Fig. 3D and thus contributed to an enhanced
quenching.
3.3. Effect of TET on membrane permeabilization to
Ni2q in the presence of other drugs which acted on
the membrane or ion channels
Could TET enhance plasma membrane permeabil-
ity to Ni2q induced by perturbations other than QS?
In the presence of Ni2q, the permeabilization by
 .non-specific detergent, Triton X-100 0.01% imme-
 .diately caused quenching Fig. 8 . The concentration
of Triton X-100 was selected such that the rate of
fluorescence quench by the introduction of Ni2q
remained similar to that found in the experiments
using 30 mgrml QS. We did not check whether such
permeabilization involved Ni2q entry alone or Ni2q
entry plus fura-2 leak-out. We observed that Triton
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X-100 at such low concentration did not cause cell
lysis but resulted in cells completely stained with
Trypan blue. Treatment with TET for 6.5 min did not
significantly affect the Triton-induced permeabiliza-
tion.
 . 2qAddition of ionomycin 0.35 mM accelerated Ni
entry; subsequent treatment with TET did not further
increase the Ni2q entry rate, but instead slightly
2q  .retarded Ni entry data not shown . In a recent
report, we showed that while SK&F 96365 a newly
2q .developed non-specific Ca channel blocker be-
2q haved as a Ca antagonist at low concentrations 3
mM causing 70% suppression of thapsigargin-
2q .activated Ca entry in HL-60 cells , high concentra-
 .tions of this drug 16–100 mM actually promoted
2q w xNi entry 21 . Here we did not observe any potenti-
ating effect of TET on Ni2q entry promoted by 20
 .mM SK&F 96365 results not shown .
3.4. The effect of TET on the basal Ni2q influx upon
modification of the plasma membrane fluidity
Membrane fluidity has been known to be posi-
w x 2qtively related to temperature 26 . At 378C, Ni
 .entry was retarded by TET Fig. 4a,b . TET also
2q  .retarded Ni entry at either a lower 278C or a
 .  .higher 478C temperature Fig. 9 . Therefore TET
 . 2qdid not enhance indeed inhibited Ni entry, al-
though the fluidity of the plasma membrane was
modulated by changes of temperature, which affected
the basal leak to Ni2q.
Fig. 8. TET did not affect Triton X-100-induced permeabiliza-
tion. After exposure of HL-60 cells in Ca2q-free HBSS to 1.2
2q  .mM Ni , Triton X-100 0.01% was added before further
 .  .treatment with TET 100 mM or HCl solvent control . The
y-axis represents fura-2 fluorescence at 360 nm excitation wave-
length. Results are the mean"S.E.M. of 4 separate experiments.
Fig. 9. Effect of TET on Ni2q entry at different temperatures.
2q  .HL-60 cells in Ca -free HBSS were equilibrated at 278C a or
 .478C b for around 4 min. Subsequently the cells were exposed
2q  .to 1.2 mM Ni and further treated with HCl solvent control or
100 mM TET. The vertical bar represents 5 fura-2 fluorescence
units at 360 nm excitation wavelength. Similar results were
obtained in another experiment.
Furthermore, ethanol has been known to cause
w xfluidization of the plasma membrane 27 , and TET
did not cause any acceleration of Ni2q entry when
the cells had been treated with 5% ethanol results
.not shown .
3.5. Effects of TET on permeabilization induced by
other cholesterol-complexing agents
It follows from the above results that TET could
only enhance permeabilization induced by QS. We
also tested whether TET could enhance permeabiliza-
tion induced by other cholesterol-complexing agents,
 . namely, filipin a polyene antibiotic and digitonin a
. w xplant glycosidic compound 20 . We were not able to
use filipin as this agent on its own produced an
intense fluorescence. Digitonin, at 1–3 mM, pro-
moted Ni2q entry at a rate similar to that promoted
by 30 mgrml QS, as shown in Fig. 4. However,
digitonin-promoted Ni2q entry was not further en-
 .hanced by 100 mM TET not shown .
3.6. Effects of lipophilic Ca2q channel blockers and
TET analogues
Diltiazem and verapamil are lipophilic Ca2q chan-
nel blockers structurally unrelated to TET. Here we
did not observe any acceleration of QS-promoted
2q  .Ni entry by 100 mM of either agent not shown .
HER and BER differ structurally from TET in a
 .very minor manner Fig. 1 . These 2 compounds, like
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Fig. 10. BER did not enhance QS-induced Ni2q entry. HL-60
cells in Ca2q-free HBSS were exposed to 1.2 mM Ni2q and 30
 .mgrml QS before being challenged with HCl solvent control ,
 .HER, TET or BER all at 100 mM . The y-axis represents fura-2
fluorescence at 360 nm excitation wavelength. Similar traces
were obtained in 2 other separate experiments.
TET, elicit Ca2q antagonistic actions in a number of
w xcell types 28–30 , and they also block thapsigargin-
2q w xactivated Ca entry in HL-60 cells 18 . Fig. 10
shows that TET and HER had a comparable potenti-
ating effect on the QS action. However, the latter was
not affected by BER.
4. Discussion
QS have been commonly used to selectively per-
meabilize the plasma membrane to probe into the
w xintracellular events 23–25,31–33 . TET, a widely
studied bis-benzylisoquinoline alkaloid, exerts multi-
ple effects on plasmalemmal ion channels and recep-
w xtors 5–15 . The major observation in this study that
TET potentiated QS-induced increase in plasmalem-
mal permeability represents a novel finding, which is
discussed below.
4.1. The permeability properties of pores formed by
QS and TET
An exposure to 30 mgrml QS for 5 min did not
cause any fura-2 leakage in HL-60 cells; however,
this treatment accelerated the entry of Ni2q but not
2q  .Mn Figs. 3, 4 and 7 . It therefore appears that the
pores formed by 30 mgrml QS on the plasma mem-
brane during the first 5 min were not large enough in
size for fura-2 movement, but enough for Ni2q to
diffuse through; for Mn2q, the pores were still poorly
permeable. To the best of our knowledge, such a
unique permeability property of the QS-formed pores
to divalent cations has not been reported before. The
sizes of QS-formed pores may well depend on the
concentrations of QS used, as well as incubation
time. Treatment of cells with 100 mgrml QS for just
2.5 min could result in a substantial fura-2 leak-out
 .Fig. 3 .
One novel action of TET reported here is the
enhancement of QS-induced permeabilization. TET
enhanced 30 mgrml QS-promoted Ni2q entry
 .without promoting fura-2 leak-out at the first 2.5
min but thereafter they synergistically promoted fura-
 .2 leakage Figs. 3–5 . It can therefore be envisaged
that during the first 2.5 min TET enhanced the size of
QS-formed pores to render Ni2q much more perme-
ant; thereafter, further incubation will develop to an
extent that the pores were large enough to permit
even fura-2 to diffuse out. If fura-2 leak-out had been
rate-determining during the first 2.5 min, then one
would expect similar fluorescence quench by added
Ni2q and Mn2q. The augmentation by TET of QS-in-
duced pore formation may well depend on the con-
centration of QS, as well as incubation time. Signifi-
cant enhancement by TET of 100 mgrml QS-promo-
ted fura-2 leak-out began in the first 2.5 min, during
which time 100 mgrml QS itself already promoted a
substantial fura-2 leakage presumably due to a faster
.  .rate of pore formation Fig. 3 . It therefore appears
that enhancement by TET also depended on the rate
of QS-induced pore formation.
4.2. Possible mechanism of the enhancement of QS
action by TET
TET has been shown to inhibit L-, T- and N-type
w xVOCC in several excitable tissues 6–9 , and block
non-voltage-gated Ca2q channels in a number of
w xnon-excitable cells including HL-60 cells 12,13,18 .
Whether TET is a selective Ca2q antagonist remains
controversial since it affects many types of Ca2q
channels and has modulatory effects on other targets
such as Ca2q-activated Kq channels, Naq,Kq-
ATPases, a-adrenoceptors and protein kinase C
w x5,14,15,34 . QS are amphiphilic and thus act as
surface-active agents on the plasma membrane
w x35,36 . Our observation that TET interfered with
QS-induced permeabilization suggests that somehow
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the effects of TET were strongly affiliated with the
plasma membrane. The latter proposal is also consis-
tent with the lipophilic nature of TET. The full
recovery of KCl-induced vascular muscle contraction
following TET inhibition required repeated wash-out
w xover 2–3 h 10 . Further, TET has been shown to
cause contraction in the venous smooth muscle via
w xa-adrenoceptor activation even after wash-out 34 .
Taken together, these findings suggest an association
of TET with the plasma membrane itself, and there-
fore challenge the view that TET binds specifically to
plasma membrane proteins, such as ion channels or
pumps.
What is the action of TET on the plasma mem-
brane? It is remarkable that TET could not accelerate
permeability changes induced by other means of per-
turbing the plasma membrane. First, TET did not
accelerate Ni2q influx promoted by drugs that induce
cation entry, such as ionomycin and SK&F 96365
 .only at higher concentrations . Second, the failure of
TET to potentiate Ni2q entry upon ethanol treatment
and temperature changes factors known to modulate
.membrane fluidity argues against the view that TET
potentiated QS-induced Ni2q entry via the modula-
tion of membrane fluidity. Furthermore, permeabi-
lization induced by Triton X-100 a detergent that
non-specifically dissociates hydrophobic interactions
.of phospholipids at the plasma membrane was not
affected by TET, suggesting that TET did not modify
the interactions between Triton X-100 and the bulk
plasmalemmal lipids. The above arguments seem to
lead to the suggestion that TET enhanced a surface
action unique to QS. Such an action might be aggre-
gation of cholesterol, a well-known effect of QS
which is believed to be the cause of QS-induced
w xpermeabilization 19,20 . The suggestion that TET
enhanced QS-induced permeabilization by potentiat-
ing QS-triggered cholesterol aggregation is in concor-
dance with our observation that ginseng saponins,
being unable to aggregate cholesterol and induce
w xpermeabilization 25 , still could not permeabilize
cells even in the presence of TET see the second
.part of Section 3 . What may await future investiga-
tion to confirm the enhancement by TET of QS-trig-
gered cholesterol aggregation is to use phospholipid-
and cholesterol-containing artificial liposomes in-
.stead of HL-60 cells , employing the protocols de-
scribed in this report.
4.3. QS-TET interaction exhibits specificity
Both QS and digitonin are glycosidic compounds
and have been well known to cause cholesterol ag-
w xgregation 19,20 . However, TET could only enhance
permeabilization induced by QS but not digitonin. It
therefore appears that TET did not enhance choles-
terol aggregation per se, but seemed to enhance
cholesterol aggregation caused specifically by QS.
Digitonin is a single glycoside while QS is a mixture
of glycosidic compounds. Digitonin and QS differ
remarkably in the lipophilic aglycon backbones and
w xthe amounts and types of sugar moieties 36,37 .
Differences in the three-dimensional structures be-
tween the QS-cholesterol and digitonin-cholesterol
complexes are to be expected. Indeed, freeze-fracture
electron micrographs of Xenopus embryonic muscle
cell membranes reveal different morphologies of
QS-cholesterol complexes irregular and rough ap-
. pearance and digitonin-cholesterol complexes scal-
. w xloped appearance 20 . Our data therefore suggest a
specificity in the molecular recognition between TET
and QS-cholesterol complexes.
The specific nature of TET-QS interaction is also
reflected by the inability of verapamil and diltiazem
 2qlipophilic Ca antagonists which are likely to parti-
tion into the plasma membrane lipid bilayer at high
w x.concentrations 38 to mimic TET in enhancing QS-
induced permeabilization. Furthermore, there is a
stringent structural requirement – R methoxyl group2
 .of TET see Fig. 1 and Fig. 10 – for QS-TET
interaction, suggesting that the interaction between
the bulk lipophilic benzylisoquinoline framework of
TET and QS was not sufficient to enhance QS action.
It is interesting to note that the R methoxyl group2
also appeared to be critical in many pharmacological
w xactions of TET, such as immunosuppression 39–41
2q w xand Ca entry blockade 18,42 .
TET and QS together enhanced the entry of Ni2q
but not Mn2q. This ion selectivity further lends sup-
port to the specific nature of the QS-TET interaction
at the plasma membrane. Such ion selectivity is also
reminiscent of the differential activation of cation
entry by SK&F 96365 in HL-60 cells: at 30 mM,
SK&F 96365 promoted the entry of Ni2q but not
2q w xMn 21 . Obviously, the subtle effects of TET and
SK&F 96365 on plasmalemmal cationic fluxes war-
rant further investigation.
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4.4. Therapeutic potential and experimental uses of
QS and TET
In summary, our data indicate that TET on its own
blocked divalent cation entry, but in the presence of
QS, TET became a potentiator of QS-induced perme-
abilization. This may exemplify the complications in
using compounds from natural sources due to drug
interactions. There are a number of therapeutic poten-
tial and experimental uses of QS and TET. For
example, QS, and its more refined preparation, Quil
w xA, have been shown to be immunopotentiating 35,43
and provide potent immune adjuvanticity for viral
w xantigens in animal models 36,44–46 . TET has been
demonstrated to be an effective hypotensive and anti-
silicotic drug in animal experiments and clinical stud-
w xies 1–4 . With respect to the employment of QS and
TET as experimental tools, QS are extensively used
in permeabilization studies, and there is an increasing
interest in using TET as a pharmacological probe for
w xvarious ion channels 5–13 . In view of such a wide
spectrum of usages, the QS-TET drug interaction
should be taken into consideration in future applica-
tions of these compounds.
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